Comments
Loading...

Axsome Therapeutics Analyst Ratings

AXSMNASDAQ
Logo brought to you by Benzinga Data
$126.79
0.520.41%
At close: -
$126.79
0.000.00%
After Hours: Mar 21, 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$212.00
Lowest Price Target1
$105.00
Consensus Price Target1
$160.24

Axsome Therapeutics Analyst Ratings and Price Targets | NASDAQ:AXSM | Benzinga

Axsome Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Axsome Therapeutics Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
4
Dec 24
6
Jan
19
Feb
3
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Needham
Baird
Morgan Stanley
Mizuho

1calculated from analyst ratings

Analyst Ratings for Axsome Therapeutics

Buy NowGet Alert
03/06/2025Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$200 → $200ReiteratesBuy → BuyGet Alert
03/03/2025Buy NowNeedham
Ami Fadia62%
$153 → $153ReiteratesBuy → BuyGet Alert
03/03/2025Buy NowBaird
Joel Beatty68%
$132 → $160MaintainsOutperformGet Alert
02/27/2025Buy NowMorgan Stanley
Vikram Purohit38%
$125 → $190MaintainsOverweightGet Alert
02/26/2025Buy NowMizuho
Graig Suvannavejh55%
$195 → $212MaintainsOutperformGet Alert
02/25/2025Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$200 → $200ReiteratesBuy → BuyGet Alert
02/24/2025Buy NowNeedham
Ami Fadia62%
$153 → $153ReiteratesBuy → BuyGet Alert
02/20/2025Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$200 → $200MaintainsBuyGet Alert
02/19/2025Buy NowTruist Securities
Joon Lee78%
$190 → $200MaintainsBuyGet Alert
02/19/2025Buy NowRBC Capital
Leonid Timashev47%
$143 → $192MaintainsOutperformGet Alert
02/19/2025Buy NowCantor Fitzgerald
Charles Duncan72%
$153 → $153ReiteratesOverweight → OverweightGet Alert
02/19/2025Buy NowNeedham
Ami Fadia62%
$133 → $153MaintainsBuyGet Alert
02/12/2025Buy NowWells Fargo
Cerena Chen50%
$140 → $160MaintainsOverweightGet Alert
02/11/2025Buy NowDeutsche Bank
David Hoang42%
→ $176Initiates → BuyGet Alert
02/11/2025Buy NowB of A Securities
Jason Gerberry62%
$143 → $167MaintainsBuyGet Alert
02/11/2025Buy NowMizuho
Graig Suvannavejh55%
$137 → $195MaintainsOutperformGet Alert
02/11/2025Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$190 → $190ReiteratesBuy → BuyGet Alert
02/10/2025Buy NowLeerink Partners
Marc Goodman73%
$110 → $150MaintainsOutperformGet Alert
02/10/2025Buy NowNeedham
Ami Fadia62%
$133 → $133ReiteratesBuy → BuyGet Alert
02/03/2025Buy NowMizuho
Graig Suvannavejh55%
$122 → $137MaintainsOutperformGet Alert
02/03/2025Buy NowTruist Securities
Joon Lee78%
$180 → $190MaintainsBuyGet Alert
02/03/2025Buy NowRBC Capital
Brian Abrahams52%
$139 → $143MaintainsOutperformGet Alert
01/31/2025Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$180 → $190MaintainsBuyGet Alert
01/29/2025Buy NowRBC Capital
Brian Abrahams52%
$139 → $139MaintainsOutperformGet Alert
01/21/2025Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$180 → $180ReiteratesBuy → BuyGet Alert
01/13/2025Buy NowNeedham
Ami Fadia62%
$133 → $133ReiteratesBuy → BuyGet Alert
01/13/2025Buy NowTruist Securities
Joon Lee78%
$150 → $180MaintainsBuyGet Alert
01/06/2025Buy NowNeedham
Ami Fadia62%
$133 → $133ReiteratesBuy → BuyGet Alert
12/31/2024Buy NowMizuho
Graig Suvannavejh55%
$124 → $122MaintainsOutperformGet Alert
12/31/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
ReiteratesBuy → BuyGet Alert
12/30/2024Buy NowNeedham
Ami Fadia62%
$130 → $130ReiteratesBuy → BuyGet Alert
12/12/2024Buy NowCantor Fitzgerald
Charles Duncan72%
$121 → $121ReiteratesOverweight → OverweightGet Alert
11/27/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$180 → $180ReiteratesBuy → BuyGet Alert
11/25/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$180 → $180ReiteratesBuy → BuyGet Alert
11/13/2024Buy NowBaird
Joel Beatty68%
$112 → $116MaintainsOutperformGet Alert
11/13/2024Buy NowNeedham
Ami Fadia62%
$130 → $130ReiteratesBuy → BuyGet Alert
11/12/2024Buy NowNeedham
Ami Fadia62%
$130 → $130ReiteratesBuy → BuyGet Alert
10/04/2024Buy NowRBC Capital
Leonid Timashev47%
$130 → $131MaintainsOutperformGet Alert
09/20/2024Buy NowCantor Fitzgerald
Charles Duncan72%
$107 → $107ReiteratesOverweight → OverweightGet Alert
09/16/2024Buy NowCantor Fitzgerald
Charles Duncan72%
$107 → $107ReiteratesOverweight → OverweightGet Alert
09/09/2024Buy NowCantor Fitzgerald
Charles Duncan72%
$107 → $107ReiteratesOverweight → OverweightGet Alert
09/06/2024Buy NowCantor Fitzgerald
Charles Duncan72%
$107 → $107ReiteratesOverweight → OverweightGet Alert
09/05/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$180 → $180ReiteratesBuy → BuyGet Alert
09/05/2024Buy NowNeedham
Ami Fadia62%
$130 → $130ReiteratesBuy → BuyGet Alert
09/03/2024Buy NowWells Fargo
Cerena Chen50%
→ $140Initiates → OverweightGet Alert
08/22/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$180 → $180ReiteratesBuy → BuyGet Alert
08/06/2024Buy NowUBS
Ashwani Verma49%
$107 → $105MaintainsBuyGet Alert
08/06/2024Buy NowRBC Capital
Leonid Timashev47%
$131 → $130MaintainsOutperformGet Alert
08/06/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$190 → $180MaintainsBuyGet Alert
08/06/2024Buy NowB of A Securities
Jason Gerberry62%
$95 → $106UpgradeNeutral → BuyGet Alert
08/06/2024Buy NowNeedham
Ami Fadia62%
$130 → $130ReiteratesBuy → BuyGet Alert
08/05/2024Buy NowNeedham
Ami Fadia62%
$130 → $130ReiteratesBuy → BuyGet Alert
07/26/2024Buy NowCantor Fitzgerald
Charles Duncan72%
$107 → $107ReiteratesOverweight → OverweightGet Alert
07/22/2024Buy NowRBC Capital
Leonid Timashev47%
$131 → $131ReiteratesOutperform → OutperformGet Alert
07/22/2024Buy NowNeedham
Ami Fadia62%
→ $130Initiates → BuyGet Alert
07/18/2024Buy NowB of A Securities
Jason Gerberry62%
$97 → $95MaintainsNeutralGet Alert
06/12/2024Buy NowMizuho
Graig Suvannavejh55%
$106 → $106ReiteratesBuy → BuyGet Alert
06/06/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$190 → $190ReiteratesBuy → BuyGet Alert
06/05/2024Buy NowRBC Capital
Leonid Timashev47%
$127 → $130MaintainsOutperformGet Alert
05/08/2024Buy NowMizuho
Graig Suvannavejh55%
$109 → $106MaintainsBuyGet Alert
05/07/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$190 → $190ReiteratesBuy → BuyGet Alert
05/07/2024Buy NowCitigroup
David Hoang42%
$127 → $125MaintainsBuyGet Alert
05/07/2024Buy NowBaird
Joel Beatty68%
$108 → $112MaintainsOutperformGet Alert
04/29/2024Buy NowMorgan Stanley
Vikram Purohit38%
$90 → $115UpgradeEqual-Weight → OverweightGet Alert
04/10/2024Buy NowCantor Fitzgerald
Charles Duncan72%
$107 → $107ReiteratesOverweight → OverweightGet Alert
04/02/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$190 → $190MaintainsBuyGet Alert
03/28/2024Buy NowMizuho
Graig Suvannavejh55%
$108 → $109MaintainsBuyGet Alert
03/26/2024Buy NowTruist Securities
Joon Lee78%
→ $150MaintainsBuyGet Alert
03/26/2024Buy NowRBC Capital
Leonid Timashev47%
$123 → $128MaintainsOutperformGet Alert
03/26/2024Buy NowCitigroup
David Hoang42%
$125 → $127MaintainsBuyGet Alert
03/26/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$180 → $190MaintainsBuyGet Alert
03/20/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$180 → $180ReiteratesBuy → BuyGet Alert
03/19/2024Buy NowBaird
Joel Beatty68%
→ $108Initiates → OutperformGet Alert
03/04/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$180 → $180ReiteratesBuy → BuyGet Alert
02/27/2024Buy NowMizuho
Graig Suvannavejh55%
$112 → $108MaintainsBuyGet Alert
02/21/2024Buy NowGuggenheim
Yatin Suneja48%
$110 → $125MaintainsBuyGet Alert
02/21/2024Buy NowRBC Capital
Leonid Timashev47%
$126 → $123MaintainsOutperformGet Alert
02/21/2024Buy NowCantor Fitzgerald
Charles Duncan72%
$108 → $103MaintainsOverweightGet Alert
02/20/2024Buy NowCantor Fitzgerald
Charles Duncan72%
→ $108ReiteratesOverweight → OverweightGet Alert
02/16/2024Buy NowMizuho
Graig Suvannavejh55%
$90 → $112MaintainsBuyGet Alert
02/06/2024Buy NowUBS
Ashwani Verma49%
→ $111Initiates → BuyGet Alert
01/25/2024Buy NowRBC Capital
Leonid Timashev47%
→ $126Initiates → OutperformGet Alert
01/22/2024Buy NowCantor Fitzgerald
Charles Duncan72%
$108 → $108ReiteratesOverweight → OverweightGet Alert
01/16/2024Buy NowPiper Sandler
David Amsellem69%
$90 → $113MaintainsOverweightGet Alert
12/26/2023Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$180 → $180ReiteratesBuy → BuyGet Alert
12/20/2023Buy NowCantor Fitzgerald
Charles Duncan72%
$108 → $108ReiteratesOverweight → OverweightGet Alert
12/13/2023Buy NowCitigroup
David Hoang42%
→ $125Initiates → BuyGet Alert
12/12/2023Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$180 → $180ReiteratesBuy → BuyGet Alert
11/07/2023Buy NowCantor Fitzgerald
Charles Duncan72%
→ $108ReiteratesOverweight → OverweightGet Alert
09/25/2023Buy NowMizuho
Graig Suvannavejh55%
→ $100ReiteratesBuy → BuyGet Alert
08/28/2023Buy NowMizuho
Graig Suvannavejh55%
→ $100ReiteratesBuy → BuyGet Alert
08/22/2023Buy NowCantor Fitzgerald
Charles Duncan72%
→ $108ReiteratesOverweight → OverweightGet Alert
08/11/2023Buy NowMizuho
Graig Suvannavejh55%
$95 → $100MaintainsBuyGet Alert
08/08/2023Buy NowB of A Securities
Jason Gerberry62%
$59 → $81UpgradeUnderperform → NeutralGet Alert
08/08/2023Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$190 → $180MaintainsBuyGet Alert
08/08/2023Buy NowPiper Sandler
David Amsellem69%
$70 → $90UpgradeNeutral → OverweightGet Alert
07/17/2023Buy NowHC Wainwright & Co.
Raghuram Selvaraju43%
$200 → $190MaintainsBuyGet Alert
06/22/2023Buy NowCantor Fitzgerald
Charles Duncan72%
→ $104ReiteratesOverweight → OverweightGet Alert
06/15/2023Buy NowGuggenheim
Yatin Suneja48%
→ $110ReiteratesBuy → BuyGet Alert
06/14/2023Buy NowMizuho
Graig Suvannavejh55%
→ $95ReiteratesBuy → BuyGet Alert

FAQ

Q

What is the target price for Axsome Therapeutics (AXSM) stock?

A

The latest price target for Axsome Therapeutics (NASDAQ:AXSM) was reported by HC Wainwright & Co. on March 6, 2025. The analyst firm set a price target for $200.00 expecting AXSM to rise to within 12 months (a possible 57.74% upside). 71 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Axsome Therapeutics (AXSM)?

A

The latest analyst rating for Axsome Therapeutics (NASDAQ:AXSM) was provided by HC Wainwright & Co., and Axsome Therapeutics reiterated their buy rating.

Q

When was the last upgrade for Axsome Therapeutics (AXSM)?

A

The last upgrade for Axsome Therapeutics Inc happened on August 6, 2024 when B of A Securities raised their price target to $106. B of A Securities previously had a neutral for Axsome Therapeutics Inc.

Q

When was the last downgrade for Axsome Therapeutics (AXSM)?

A

There is no last downgrade for Axsome Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Axsome Therapeutics (AXSM)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axsome Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axsome Therapeutics was filed on March 6, 2025 so you should expect the next rating to be made available sometime around March 6, 2026.

Q

Is the Analyst Rating Axsome Therapeutics (AXSM) correct?

A

While ratings are subjective and will change, the latest Axsome Therapeutics (AXSM) rating was a reiterated with a price target of $200.00 to $200.00. The current price Axsome Therapeutics (AXSM) is trading at is $126.79, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch